Group 1 - RIPRETINIBUM

Auto-translated from Polish

Original title: Grupa 1 - RIPRETINIBUM

Centrum Onkologii im. Franciszka Łukaszczyka w Bydgoszczy

Published: Oct 21, 2026

Updated: Oct 22, 2026

Source: TED - Tenders Electronic Daily (EU)

About This Opportunity

This is a supplies contract in the health and medical services sector, with a focus on Pharmaceuticals. Located in Poland, Europe, this opportunity is open to firms and consortiums.

Published through TED - Tenders Electronic Daily (EU), a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. Interested parties should review the full documentation on the original source before submitting their proposal.

Description

Original language: Polish

This tender, originating from Poland and sourced via TED, is for "Grupa 1 - RIPRETINIBUM" (Group 1 - RIPRETINIBUM). This clearly indicates a procurement for a specific pharmaceutical product, RIPRETINIBUM, likely for medical or research purposes. The contracting authority is seeking the supply of this active pharmaceutical ingredient or a finished dosage form. Typical requirements for such a tender in Poland include strict adherence to pharmaceutical quality standards (e.g., GMP - Good Manufacturing Practice), pharmacopoeia specifications (e.g., EP, USP), and relevant regulatory approvals from Polish or European health authorities. Bidders must provide detailed product documentation, including certificates of analysis, safety data sheets, and proof of regulatory compliance. The tender will likely specify the required quantities, packaging, storage conditions, and delivery timelines. Reliability of supply, quality assurance, and adherence to all legal and regulatory requirements for pharmaceuticals are critical evaluation factors.

Data provenance

This notice is sourced from TED - Tenders Electronic Daily (EU) and was originally published on October 21, 2026. Last refreshed today. Original language: Polish. BidsFactory mirrors official procurement notices and links back to the source for full legal text.

About Centrum Onkologii im. Franciszka Łukaszczyka w Bydgoszczy

Centrum Onkologii im. Franciszka Łukaszczyka w Bydgoszczy has issued 118 procurement notices on BidsFactory, including 8 currently open and 44 awarded contracts. Activity concentrates in Health & Medical, Information & Communication Technology, and General Supplies & Services. All notices are published for Poland. Notices are distributed via TED - Tenders Electronic Daily (EU). Most recent publication: October 21, 2026.

Frequently asked questions about this tender

How can I submit a bid?

Visit TED - Tenders Electronic Daily (EU) to access the full notice, required documents, and submission instructions provided by the contracting authority.

Who is the contracting authority?

This notice was issued by Centrum Onkologii im. Franciszka Łukaszczyka w Bydgoszczy in Poland. The authority is responsible for evaluating bids, awarding the contract, and managing performance.

What type of contract is this?

This is a Supplies contract in the Health & Medical sector. The classification helps bidders match the opportunity to their qualifications and registered scope of supply.

Where will the contract be performed?

The contract is for delivery in Poland. Foreign bidders should review local registration, taxation, and any in-country presence requirements before submitting.